Antengene announces ESMO 2026 poster presentations for ATG-022, ATG-037

Antengene announced that two clinical abstracts have been accepted for poster presentation at ESMO 2026 in Madrid. The presentations will cover Phase II results for the Claudin 18.2 ADC ATG-022 in advanced gastric or gastroesophageal junction cancer, as well as updated Phase Ib/II data for the oral CD73 inhibitor ATG-037 combined with pembrolizumab in CPI-resistant melanoma.

Antengene posted a press release on two clinical abstracts accepted for poster presentation at ESMO 2026 in Madrid, Oct. 23-27. * Abstracts cover Phase II results for Claudin 18.2 ADC ATG-022 in advanced gastric or gastroesophageal junction cancer. * Updated Phase Ib/II data for oral CD73 inhibitor ATG-037 with pembrolizumab in CPI-resistant melanoma will also be presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN07689) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)